Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth In Vivo

Glioblastoma is the most common and aggressive primary brain tumor in adults. Median survival time remains at 16-20 months despite multimodal treatment with surgical resection, radiation, temozolomide and tumor-treating fields therapy. After genotoxic stress glioma cells initiate cytoprotective auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Radin, Daniel P., Smith, Gregory, Moushiaveshi, Victoria, Wolf, Alexandra, Bases, Robert, Tsirka, Stella E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048484/
https://www.ncbi.nlm.nih.gov/pubmed/35494072
http://dx.doi.org/10.3389/fonc.2022.852940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048484/
https://www.ncbi.nlm.nih.gov/pubmed/35494072
http://dx.doi.org/10.3389/fonc.2022.852940

Ejemplares similares